2012 revenue: $8.7 billion
2011 revenue: $8.3 billion
Year in review: The devicemaker ($STK) had a solid year, boosting net sales growth 4.2% in a tough economy. Even fourth-quarter revenue grew a robust 5.5%, hitting the $2.3 billion mark, thanks to healthy growth in neurotechnology and spine-product sales, and a heady increase in its reconstructive and trauma and extremities/orthopedics businesses. But talk about ending on a negative note. Stryker spent $133 million to deal with costs relating to the recall of its Rejuvenate and ABG II all-metal hip implants, and expectations are that the price tag could hit the $390 million mark. That, combined with general restructuring costs, dragged net income in those last few months of 2012 down 32.7%, to $270 million. Still, Stryker foresees further growth in 2013, which is expected to be propelled even more once it closes its long-awaited $764 million acquisition of Chinese orthopedic device manufacturer Trauson Holdings.
Recall charges drag down Stryker's strong Q4 sales